Chronic Kidney Disease Drugs Market, by Drug Type (ACE Inhibitors, B-blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-stimulating Agents (ESAs), Phosphate Binders, and Others), by Route of Administration (Oral, Intravenous, and Subcutane

Chronic Kidney Disease Drugs Market, by Drug Type (ACE Inhibitors, B-blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-stimulating Agents (ESAs), Phosphate Binders, and Others), by Route of Administration (Oral, Intravenous, and Subcutaneous), by Patient Type (Dialysis and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Chronic kidney disease is the lasting damage to the kidneys that can get worse over time. If the damage is very bad, kidneys may stop working. This is called kidney failure, or end-stage renal disease (ESRD). In this condition, kidneys are damaged and cannot filter blood in the usual way. If kidney disease gets worse, wastes can build to high levels in patient’s blood and make the patient feel sick. Chronic kidney disease may be caused by diabetes, high blood pressure and other disorders. Damage to kidneys is usually permanent. Although the damage cannot be fixed, symptoms such as muscle twitches, cramps, fatigue, heart problems, swelling of feet and ankles can be managed to control by certain medications such as ACE inhibitors and calcium channel blockers.
Market Dynamics
Rising prevalence of chronic kidney disease, increasing launches & approval of new products for the treatment of chronic kidney disease, and increasing adoption of inorganic growth strategies such as collaboration and acquisition by key players operating in the market are expected to drive the growth of global chronic kidney disease drugs market over the forecast period. For instance, In August 2021, GSK submitted a Japanese New Drug Application (JNDA) to the Ministry of Health, Labor and Welfare seeking approval for Duvroq (daprodustat) tablets, indicated for the treatment of anemia associated due to chronic kidney disease (CKD). Later, on 29 June 2020, GSK received approval for Duvroq (daprodustat) from the Ministry of Health, Labor and Welfare, Japan.
Key features of the study:
This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic kidney disease drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market
Detailed Segmentation:
Global Chronic Kidney Disease Drugs Market, By Drug Type:
ACE Inhibitors
B-blockers
Calcium Channel Blockers
Loop Diuretics
Erythropoiesis-stimulating Agents (ESAs)
Phosphate Binder
Others
Global Chronic kidney Disease Drugs Market, By Route of Administration:
Oral
Intravenous
Subcutaneous
Global Chronic kidney Disease Drugs Market, By Patient Type:
Dialysis
Others
Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Chronic Kidney Disease Drugs Market, By Region:
North America
By Drug Type:
ACE Inhibitors
B-Blockers
Calcium Channel Blockers
Loop Diuretics
Erythropoiesis-Stimulating Agents (ESAs)
Phosphate Binders
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Patient Type:
Dialysis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Type:
ACE Inhibitors
B-Blockers
Calcium Channel Blockers
Loop Diuretics
Erythropoiesis-Stimulating Agents (ESAs)
Phosphate Binders
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Patient Type:
Dialysis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type:
ACE Inhibitors
B-Blockers
Calcium Channel Blockers
Loop Diuretics
Erythropoiesis-Stimulating Agents (ESAs)
Phosphate Binders
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Patient Type:
Dialysis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type:
ACE Inhibitors
B-Blockers
Calcium Channel Blockers
Loop Diuretics
Erythropoiesis-Stimulating Agents (ESAs)
Phosphate Binders
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Patient Type:
Dialysis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type:
ACE Inhibitors
B-Blockers
Calcium Channel Blockers
Loop Diuretics
Erythropoiesis-Stimulating Agents (ESAs)
Phosphate Binders
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Patient Type:
Dialysis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
ACE Inhibitors
B-Blockers
Calcium Channel Blockers
Loop Diuretics
Erythropoiesis-Stimulating Agents (ESAs)
Phosphate Binders
Others
By Route of Administration:
Oral
Intravenous
Subcutaneous
By Patient Type:
Dialysis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Amgen, Inc. *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Teva Pharmaceutical Industries Ltd.
Pfizer, Inc.
AstraZeneca Plc
Hoffmann La Roche Ltd.
Sanofi S.A.
Kissei Pharmaceutical Co. Ltd.
AbbVie Inc.
Reata Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Ardelyx, Inc.
“*” marked represents similar segmentation in other categories in the respective section